Beijing Kawin Technology Share-holding Co Ltd (688687) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beijing Kawin Technology Share-holding Co Ltd (688687) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥26.41 Million ≈ $3.86 Million USD) by net assets (CN¥1.83 Billion ≈ $267.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Beijing Kawin Technology Share-holding Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2025)
This chart illustrates how Beijing Kawin Technology Share-holding Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Beijing Kawin Technology Share-holding C (688687) net assets for net asset value and shareholders' equity analysis.
Beijing Kawin Technology Share-holding Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beijing Kawin Technology Share-holding Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asia Aviation Public Company Limited
BK:AAV
|
0.385x |
|
CJ Corp 4P Pref
KO:00104K
|
0.102x |
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
0.070x |
|
Panoro Energy ASA
OL:PEN
|
0.139x |
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
0.000x |
|
Manitowoc Company Inc
NYSE:MTW
|
0.040x |
|
Binh Minh Plastics JSC
VN:BMP
|
0.139x |
|
YTL Hospitality REIT
KLSE:5109
|
0.012x |
Annual Cash Flow Conversion Efficiency for Beijing Kawin Technology Share-holding Co Ltd (2009–2025)
The table below shows the annual cash flow conversion efficiency of Beijing Kawin Technology Share-holding Co Ltd from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see 688687 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥1.74 Billion ≈ $254.60 Million |
CN¥110.29 Million ≈ $16.14 Million |
0.063x | +14.30% |
| 2024-12-31 | CN¥1.88 Billion ≈ $275.15 Million |
CN¥104.29 Million ≈ $15.26 Million |
0.055x | -21.79% |
| 2023-12-31 | CN¥1.79 Billion ≈ $261.23 Million |
CN¥126.60 Million ≈ $18.53 Million |
0.071x | -11.02% |
| 2022-12-31 | CN¥1.68 Billion ≈ $246.10 Million |
CN¥134.05 Million ≈ $19.62 Million |
0.080x | +14.04% |
| 2021-12-31 | CN¥1.69 Billion ≈ $246.93 Million |
CN¥117.94 Million ≈ $17.26 Million |
0.070x | -54.60% |
| 2020-12-31 | CN¥853.63 Million ≈ $124.91 Million |
CN¥131.42 Million ≈ $19.23 Million |
0.154x | +15.43% |
| 2019-12-31 | CN¥771.85 Million ≈ $112.95 Million |
CN¥102.94 Million ≈ $15.06 Million |
0.133x | +44.82% |
| 2018-12-31 | CN¥654.87 Million ≈ $95.83 Million |
CN¥60.31 Million ≈ $8.83 Million |
0.092x | +297.24% |
| 2017-12-31 | CN¥612.36 Million ≈ $89.61 Million |
CN¥14.20 Million ≈ $2.08 Million |
0.023x | +55.63% |
| 2015-12-31 | CN¥545.83 Million ≈ $79.87 Million |
CN¥8.13 Million ≈ $1.19 Million |
0.015x | -92.81% |
| 2014-12-31 | CN¥239.73 Million ≈ $35.08 Million |
CN¥49.67 Million ≈ $7.27 Million |
0.207x | +172.70% |
| 2013-12-31 | CN¥220.74 Million ≈ $32.30 Million |
CN¥16.77 Million ≈ $2.45 Million |
0.076x | -56.11% |
| 2012-12-31 | CN¥163.93 Million ≈ $23.99 Million |
CN¥28.38 Million ≈ $4.15 Million |
0.173x | -34.24% |
| 2011-12-31 | CN¥122.53 Million ≈ $17.93 Million |
CN¥32.26 Million ≈ $4.72 Million |
0.263x | -2.90% |
| 2010-12-31 | CN¥92.84 Million ≈ $13.59 Million |
CN¥25.17 Million ≈ $3.68 Million |
0.271x | -39.47% |
| 2009-12-31 | CN¥38.91 Million ≈ $5.69 Million |
CN¥17.43 Million ≈ $2.55 Million |
0.448x | -- |
About Beijing Kawin Technology Share-holding Co Ltd
Beijing Kawin Technology Share-Holding Co., Ltd., a biopharmaceutical company, provides treatment solutions for viral and immune diseases in China and internationally. The company offers recombinant human interferon alfa-2b injection; interferon alfa-2b vaginal effervescent tablets; coblopasvir hydrocholoride capsules; sofosbuvir tablets; peginterferon alfacon-2 injection; and compound glycyrrhiz… Read more